EGFR/HER2-IN-18

EGFR/HER2-IN-18 is a stable EGFR/HER2 dual inhibitor with IC50 values of 0.09 (EGFR) and 0.08 μM (HER2) respectively. EGFR/HER2-IN-18 exhibits broad-spectrum anti-cancer activity. EGFR/HER2-IN-18 induces MCF-7 cells apoptosis and inhibits the cell cycle. EGFR/HER2-IN-18 can be used for the study of breast cancer[1].

Product Specifications

UNSPSC

12352005

Target

EGFR

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(N/N=C1SC=C(C2=CC=C(C)C=C2)N/1C3=CC=C(Br)C=C3)C4=CC=CC(NC5=C6C(N(C7=CC=CC=C7)N=C6)=NC=N5)=C4

Molecular Formula

C34H25BrN8OS

Molecular Weight

673.58

References & Citations

[1]Salem IM, et al. Exploitation of novel pyrazolo[3,4-d]pyrimidine scaffold tethered to thiazole as potential EGFR/HER2 dual kinase inhibitor to overcome lapatinib resistant breast cancer: Design, synthesis, in silico docking and molecular dynamic simulation. Bioorg Chem. 2025 Jun 3;163:108671.